NBPF11

Across TCGA pan-cancer cohorts, NBPF11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NBPF11 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher NBPF11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NBPF11 expression acts as an unfavorable survival marker.

KIRP, LUSC, and UCEC are the cancer types where NBPF11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	DFS	Median	All	0.037	0.920	<.001	24	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	20	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	OS	Median	III,IV	0.265	0.711	.001	10	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	DFS	Median	All	0.206	0.585	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NBPF11–KIRP (DFS)

Open the KIRP breakdown →